A Message from Publisher and CEO Ted Slafsky: I encourage you all to read today’s sponsored content article from SPARx, a division of Comprehensive Pharmacy Services, about the importance of relationships with key stakeholders in hospital-based specialty pharmacy. The ability
…Category: Pharma Industry
Hospitals and Other Providers Ask HHS to Halt Lilly and Merck’s Clampdowns on 340B; Companies Defend Their Positions
The U.S. Health and Human Services Department (HHS) should halt drug manufacturers Eli Lilly and Merck’s recent separate actions to curtail or
…A Message from Publisher and CEO Ted Slafsky: We recently welcomed FQHC 340B Compliances Services to our growing list of sponsors. In today’s sponsored content article, FQHC 340B Lead Consultant Michael Gonzalez offers five great tips on how covered entities can
…A note from Publisher and CEO Ted Slafsky: Our sponsors are 340B’s industry leaders and we are proud to showcase their innovative solutions and guidance to help you implement and comply with this complex program. Click on the button
…A note from 340B Report CEO and Publisher Ted Slafsky: Please join us in welcoming Comprehensive Pharmacy Services to our growing group of 340B Report sponsors! And I hope you enjoy a new column from
…A note from 340B Report CEO and Publisher Ted Slafsky: I encourage all of you to read Trellis Rx Chief Pharmacy Officer Jerry Buller’s great article in today’s issue about how 340B health systems can leverage
…
DOJ Says Mallinckrodt Owes Medicaid Hundreds of Millions in Rebates, but Is Silent About 340B Overcharges
The U.S. Justice Department is suing drug manufacturer Mallinckrodt for allegedly
…
340B Providers Could Face Drug Access Challenges Due to Coronavirus
In theory, federal law and 340B program guidance should protect 340B entities from shouldering an unfair
…Drug manufacturers are doing a better job of providing the Health Resources and Services Administration (HRSA) with timely and accurate data needed to verify their 340B ceiling prices, the head of the federal 340B drug pricing program indicated today. Nonetheless,
…